Access the full text.
Sign up today, get unlimited access with DeepDyve Pro!
maladaptive cardiac remodelling in post -MI hearts via sustained release of EVs. Encapsulated CSCs avoid immune rejection protected within the semi-permeable inner membrane bilayer of the TheraCyte implant ...
artery ligation to induce MI. Left ventricular ejection fraction (LVEF) was similar between W8B2+ CSC group and control group before MI and at 1 week post -MI. At 4 weeks post -treatment, implantation ...
survival of tissue in allogeneic setting up to 1 year post - implantation [127, 128]. Recently, mouse islets and human fetal islet-like clusters macroencapsulated in the device were shown to survive ...
the underlying mechanism of protection. Before jumping into clinical practice, many questions remain unanswered regarding the best cell type, the source of cells, the route of delivery, the timing ...
MSC EVs carry cargo responsible for MSC properties . This study suggests that EP4 antagonist-elicited MSC EVs may replace MSCs in therapy for CNS disease because both of their increased therapeutic ...
was partially attributed to COX2/PGE2 expression. The present study demonstrates that inflammatory stimulation of MSCs renders release of EVs that have enhanced anti-inflammatory properties partially due to COX2 ...
liquid biopsy a challenge before moving into an evaluation of current technological progress. Then, a framework for evaluation of the technologies is presented with special attention to throughput, capture ...
Access the full text.
Sign up today, get unlimited access with DeepDyve Pro!